



CATAPULT
Medicines Discovery



WE SHARE'S GRANT TERMS

WE SHARE'S INTENTION

Stichting We Share Ventures ("We Share") is a legal entity incorporated under the laws of Netherlands, with its head office located at Anna van Hannoverstraat 4, Bldg H010, 2595BJ The Hague, The Netherlands.

The purpose of We Share is to promote and support initiatives aimed at achieving the Sustainable Development Goals (hereinafter referred to as "the SDGs") to improve the lives of people or communities in disadvantaged situations in such a way that the most basic needs of life can be met.

The idea underlying We Share is that in today's era, when we are confronted almost daily with the disastrous consequences of continuous overconsumption. Almost everyone - individuals, companies, governments and other institutions - is convinced that taking measures no longer can be postponed. In the meantime, lots of people seem willing to sacrifice a small part of their own success or income to bring the SDGs closer, for a dignified existence for everyone. With these contributions, We Share can help students and social entrepreneurs - hereinafter 'the Changemakers' - get started and bring the SDGs closer, whereby we prioritize the people who have been left behind so far.

These terms listed below relate to funding to be provided by We Share to Changemakers. At We Share, we do not want the lack of funding to hold back Changemakers with innovative ideas to help the world attaining the SDGs. Through We Share, eligible Changemakers ("Applicants") can apply for a grant or other forms of funding up to a maximum of € 300,000.

We Share's funds are raised amongst all members of society: corporates, SMEs, individuals, charities and (non-)governmental institutions are challenged to share a little part of their success with We Share with the intention to fuel innovations which help to realize the SDGs.

GENERAL

These terms apply to start-ups that wish to submit an application for consideration under the Medicines Discovery Catapult ("MDC") and We Share Funding Programme ("Programme") and cover any application up to the point that a grant is awarded, at which point these terms will cease to apply. Successful Applicants will then enter into a new separate written contract with We Share, covering the award of the grant and associated terms.

Medicines Discovery Catapult will not be involved in any funding agreements of the successful applicants (including but not limited to any financial obligations placed on successful Applicant in exchange for the grant funding). However, where relevant MDC will provide ongoing support to successful applicants through access to expertise, knowledge and networks through its Syndicate programmes.

HOW TO APPLY

Applications for funding can be submitted to We Share via or with the recommendation of one of our partners. Each application is assessed independently by We Share. Applications are assessed on, among other things:


- the compositions and capabilities of the founders' team;
- the potential impact of the product or services;
- the phase the Applicant company is in;
- We Share's estimate of the chance of success;
- but most important of all is that the start-up and its founders support the Sharing Forward principle (see below).

Please note that because we actively fundraise philanthropic donations, we can only support as many projects as our funds allow us to. So, we can give no guarantees! In your application form, we will ask you for the total amount of funding you would like, and also the minimum amount you require to generate the data you need to move your project to its next stage. We always aim to fundraise the full amount, but if this is not possible, we hope that we will be able to provide you with the minimum funding you need.

WE SHARE'S FUNDING RULES

For each grant an agreement between We Share, the Applicant and its founders will be drafted. The agreement specifies for which purpose/project the grant will be provided. We Share expects the Applicant and its founders to guarantee that a grant will only be used for the agreed purpose.

A grant may be released in several milestone payments, subject to realizing clearly defined and pre-agreed milestones.





SHARING FORWARD

We Share does not demand for any repayment of its grants. However, We Share expects the Applicant and its founders to commit to We Share's Sharing Forward Philosophy. This implies that we expect from the Applicant and its founders that, if and when their hard work pays off and they become successful, they are willing to pledge to share a little bit of their success with the next generation of start-ups that apply for support from We Share.

Such a pledge is not a legally enforceable obligation but rather a moral commitment, that will be outlined within the written grant funding agreement the Applicant will negotiate with We Share. Although the exact mechanism by which Applicants decide to share their success does not need to be defined within the grant agreement, it is expected that Applicants are willing to pledge their commitment to the Sharing Forward principle.

We Share would be happy to discuss and work out possible ways for Applicants to share their success moving forwards. Below are some examples of how Applicants can fulfill such a promise. We Share would also be happy to discuss other possible forms to fulfill this pledge.

- Once successful and financially stable, the Applicant could choose We Share as their charity of choice for philanthropic donation.
- The founders could share a small part - say 1 or 2% - of their future net income with We Share.

APPLICANT REQUIREMENTS

The Applicant may have or is planning to incorporate its activities into a company or other legal form, with the ultimate goal of contributing to a solution for the SDGs. An Applicant can submit an application for a grant to We Share if - in addition to the above one or more relevant SDGs - the following conditions are met:

- the Applicant started no longer than five years ago (greenfield);
- the Applicant has an innovative solution to a social problem;
- there is a proof of concept and a concrete prospect on turnover. However, the project is not yet break even, let alone profitable;
- the traditional capital markets (banks, investors) are not yet interested to provide funding on common terms;
- the Applicant has drawn up a plan, which shows, among other things:
 1. what the product or service is;
 2. which target group(s) the social entrepreneur wants to serve;
 3. how to reach those target groups;
 4. structure of the organization;
 5. a cost-benefit analysis;
 6. cash flow forecast;
- the Applicant's team consists of 2 to 4 passionate, creative entrepreneurs, who lead the Applicant, and have been working together for some years (the longer, the better);
- the Applicant and each of the founders endorse the Sharing Forward concept of We Share.

REQUIREMENTS FOR APPLICANTS TO THE MDC AND WE SHARE FUNDING PROGRAMME (“PROGRAMME”)

In addition to the above requirements for Applicants to the Programme, projects or Applicants must:

- Be focused on early-stage drug discovery (preclinical) with a maximum budget of €300,000. We Share is happy to explore co-funding projects with other philanthropic funders, if the Applicant can demonstrate proof that funding for the total cost of the project has been secured;
- Have a maximum duration of 2 years from the date the grant is awarded;
- Clearly define the patient need that will be addressed and the impact they expect to achieve;
- Ideally have a lead asset, with proof-of-concept in animal models and/or disease linkage, solid IP protection and comprehensive data packages, enabling the best chance of success to translate to the clinic;
- Be focused on advancing the preclinical development (prior to phase 1) of novel therapeutics that have the potential to transform health outcomes for people with Cystic Fibrosis (CF), hearing disorders or psychiatric disorders (see Appendix 1).


Examples of proposals in scope include:

- Pharmacokinetics/Pharmacodynamics (PK/PD) studies;
- Safety/toxicology studies;
- Drug repositioning/repurposing (preliminary data supporting the proposed approach is required);
- Identification/validation of methods or outcomes that could be used for one or more of the following: Patient selection/stratification for clinical trials; Robust measurement of treatment responses in clinical trials;
- Novel drug delivery methods;
- Theragnostics;

All therapeutic modalities will be considered, including small molecule, biologics, cell and gene therapies and complex medicines.

Applications will not be accepted in the following areas:

- Basic research into disease causes and underpinning biology.
- The development of devices (except devices to enable improved drug delivery) or software.
- Clinical studies or the optimization of clinical protocols.
- Health service studies.



WE SHARE
WE SHARE
WE SHARE

CATAPULT
Medicines Discovery



APPENDIX 1: SCOPE OF PSYCHIATRIC DISORDERS

Projects will be focused on novel therapeutics or technologies that have the potential to transform health outcomes for people living with the following mental health conditions:

- Psychotic disorders
- Depressive disorders (including bipolar)
- Anxiety disorders
- OCD
- Cognitive disorders
- Autism Spectrum Disorders
- Psychiatric symptoms associated with dementia